Brief: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation For Ganaxolone In The Treatment Of Lennox-Gastaut Syndrome
22/03/2023 13:02
March 22 (Reuters) - Marinus Pharmaceuticals Inc
MRNS.O :
* MARINUS PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG
DESIGNATION FOR
GANAXOLONE IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME
* MARINUS PHARMACEUTICALS INC - EXPECTS TO INITIATE A
MULTIPLE
ASCENDING DOSE STUDY OF A SECOND GENERATION GANAXOLONE
FORMULATION IN Q2 OF 2023
* MARINUS PHARMACEUTICALS INC - PLANNING TO FINALIZE
CLINICAL
PROGRAM DESIGN FOR LGS IN SECOND HALF OF THIS YEAR
Source text for Eikon: ID:nBw9k7snwa
Further company coverage: MRNS.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Marinus Pharmaceuticals
See all newsU.S. RESEARCH ROUNDUP- Axsome Therapeutics, Ducommun, Vacasa
Brief: Immedica To Acquire Biopharmaceutical Company Marinus Pharmaceuticals
Marinus Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Appfolio, S&P Global, Uber
U.S. STOCKS ON THE MOVE-Newmont, Monopar Therapeutics, TKO Group